Catalent to Showcase Expertise at BPI East 2025 Conference & Exhibition

Catalent is a leading global contract development and manufacturing organization (CDMO) participating in the BioProcess International (BPI) Conference & Exhibition from September 15-18, 2025. The company will showcase its GPEx Lightning Cell Line Development Technology and New Developability Assessment & Formulation Development Services. Catalent experts will lead speaking sessions on bioprocessing technologies and network with industry leaders.

The global cytotoxic drugs and HPAPI manufacturing market is poised for significant growth, driven by advances in clinical pharmacology, oncology research, and the increasing demand for targeted therapies. According to a recent report by ResearchAndMarkets.com, the market is expected to grow from USD 11.7 billion in 2025 to USD 39.9 billion by 2035, at a CAGR of 11.6% during the forecast period [1].

The market is characterized by a high level of fragmentation, with over 140 players offering contract manufacturing services for highly potent compounds. These players range from new entrants to established companies across key geographical regions. The report highlights that 70% of service providers possess analytical testing capability for HPAPIs, underscoring the importance of advanced technology in this domain.

A notable trend in the market is the growing interest in outsourcing manufacturing operations. This is attributed to the complexity of HPAPI production, which requires specialized containment and protective strategies. The report notes that very large players are likely to dominate the market, with commercial-scale operations capturing the largest share. Antibody Drug Conjugates (ADCs) are one of the most popular classes of highly potent compounds, with over 30 players offering contract manufacturing/conjugation services for such biopharmaceuticals.

The market is segmented based on various factors, including type of product, company size, scale of operation, type of molecule, and type of highly potent finished dosage form. The HPAPI segment occupies the largest share of the market, with biologics being the fastest-growing segment. Oral finished dosage forms (FDFs) are expected to dominate the market during the forecast period due to their cost-efficiency and patient convenience.

Geographically, Europe is expected to capture the largest share of the market, followed by Asia-Pacific, which is anticipated to grow at a higher CAGR. Key players in the market include AbbVie, Cambrex, Catalent, Pfizer, CentreOne, and others, each offering a range of services and capabilities.

In summary, the cytotoxic drugs and HPAPI manufacturing market is witnessing steady growth, driven by technological advancements, outsourcing trends, and the increasing demand for targeted therapies. The market is characterized by a high level of fragmentation and specialization, with very large players and commercial-scale operations dominating the landscape.

References:
[1] https://www.globenewswire.com/news-release/2025/08/21/3136966/28124/en/Cytotoxic-Drugs-HPAPI-Manufacturing-Market-Industry-Trends-and-Global-Forecasts-to-2035-Over-140-Players-Now-Active-in-HPAPI-Cytotoxic-Drug-Contract-Manufacturing.html